The benefits and challenges of incorporating biomarkers into the development of anticancer agents have been increasingly discussed. In many cases, a sensitive subpopulation of patients is determined based on pre-clinical data and/or by retrospectively analyzing clinical trial data. Prospective exploration of sensitive subpopulations of patients may enable us to efficiently develop definitively effective treatments, resulting in accelerated drug development and a reduction in development costs. We consider the development of a new molecular-targeted treatment in cancer patients. Given preliminary but promising efficacy data observed in a phase I study, it may be worth designing a phase II clinical trial that aims to identify a sensitive subpopulation. In order to achieve this goal, we propose a Bayesian randomized phase II clinical trial design incorporating a biomarker that is measured on a graded scale. We compare two Bayesian methods, one based on subgroup analysis and the other on a regression model, to analyze a time-to-event endpoint such as progression-free survival (PFS) time. The two methods basically estimate Bayesian posterior probabilities of PFS hazard ratios in biomarker subgroups. Exten-1 sive simulation studies evaluate these methods' operating characteristics, including the correct identification probabilities of the desired subpopulation under a wide range of clinical scenarios. We also examine the impact of subgroup population proportions on the methods' operating characteristics. Although both methods' performance depends on the distribution of treatment effect and the population proportions across patient subgroups, the regression-based method shows more favorable operating characteristics.
INTRODUCTION
Recently, the benefits and challenges of incorporating biomarkers into the development of anti-cancer agents have been increasingly discussed [1] . Many clinical trials are conducted to develop new molecular-targeted anticancer agents that are likely to benefit only a subset of patients. If a clinical trial is performed in a broad population of patients, which includes insensitive as well as sensitive patients, any effect of a new agent on the sensitive subset of patients may be missed. Therefore, drug development should aim to optimize the target population of patients for treatment by appropriately focusing on patients who could obtain a sufficient benefit from a molecular-targeted agent.
In addition, identifying the sensitive subset of patients may be a vital process in clinical development in terms of speeding up the drug development process and reducing development costs [2, 3, 4, 5] .
The following two examples of clinical development represent two different extremes in the approach to this problem. First, trastuzumab, which is a humanized monoclonal antibody with high specificity for the human epidermal growth factor receptor 2 (HER2) protein, demonstrated high anti-tumor activity in patients with HER2-overexpressing metastatic breast cancer [6, 7, 8] . Based on preclinical and clinical data that strongly supported the existence of a sensitive subpopulation of patients, the clinical development of trastuzumab prospectively focused on studying the agent in HER2-overexpressing breast cancer patients. Secondly, during the development of monoclonal antibodies targeting epidermal growth factor receptor (EGFR), such as panitumumab, and EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib, patients were enrolled in clinical trials without preselection based on EGFR status or other biomarkers [6, 7] . For example, Amado et al. [9] retrospectively analyzed whether the effect of panitumumab on progression-free survival (PFS) in patients with metastatic colorectal cancer differed by KRAS status and showed a significant treatment effect in the wild-type KRAS subgroup.
That is, in the first case, solid prior data enabled clinical investigators to prospectively design subsequent clinical trials to develop a molecular-targeted agent in a patient subpopulation identifiable with a biomarker assay. In the other case, retrospective subgroup analysis of a phase III trial conducted in unselected patients was able to successfully identify a sensitive patient subpopulation. In many cases, however, the reality may lie in between these two cases.
If a study population of patients contains non-sensitive subpopulations, a much larger sample size would be required to establish statistically significant results in a final confirmatory phase III trial [10] . When considering the entire course of a new agent's clinical development, therefore, conducting a properly designed phase II trial may be key to raising the "success probability" of a subsequent phase III trial. In particular, pharmacogenetically developed drugs often rely on assays to measure target expression levels (e.g., HER2 or EGFR) on a graded scale; these levels are then dichotomized to define two subsets of patients with positive or negative status. We call the subset of patients with positive status the sensitive subpopulation. In this paper, we consider identifying the sensitive subpopulation using a graded-scale biomarker in a randomized phase II clinical trial to develop a new molecular-targeted agent. In order to design the phase II trial, we adopt a Bayesian approach for the decision-making flexibility it affords during the exploratory phase of clinical development. We compare two Bayesian methods, one based on subgroup analysis and the other on a regression model, in terms of their performance in identifying a sensitive subpopulation. In addition, we consider interim analyses to prematurely terminate the trial due to futility.
As reviewed by Yin [11] , there is a substantial literature on study designs that are used to identify sensitive patient subpopulations, including Jiang et al. [10] , Wang et al. [12] , Brannath et al. [13] , Eickhoff et al. [14] , and Jenkins et al. [15] proposed adaptive two-stage designs in which the patient subset(s) specified in the first stage is used to evaluate the treatment effect in the second stage. Their proposed study designs presume that two mutually exclusive patient subgroups are determined in advance on the basis of preclinical research or a separate exploratory study. Our focus is simply on identifying a sensitive patient subpopulation in the phase II stage, although the above study designs consider phase II/III or phase III trial settings. This paper is organized as follows. In Section 2, we provide a motivating example. Section 3 outlines the study design of a Bayesian randomized phase II clinical trial to identify a sensitive patient subpopulation. We conduct extensive simulation studies to examine the operating characteristics of our proposed study design in Section 4. We close with a brief discussion in Section 5.
A MOTIVATING EXAMPLE
In this section, we present a case study based on the actual clinical development of a new molecular-targeted monoclonal antibody. Pre-clinical and clinical works suggested that anti-tumor activity of the new antibody should depend significantly on the target protein amounts. In this study the intensity of the biomarker expression is defined using a graded scale (e.g., 0, 1+, 2+, 3+), with higher values indicating higher expression.
Results from a phase I dose-finding clinical trial suggested a possible association between biomarker expression and the efficacy of the antibody, that is, longer PFS time tended to be observed in patients with higher expression (e.g., 2+ and 3+). In this study, we assume monotonicity in the efficacy of the new agent with respect to the biomarker grade.
While effective first-line therapies exist for patients with advanced stages of cancer and poor prognoses, in particular hepatocellular carcinoma (HCC) and pancreatic car-cinoma, no standard second-line treatments have yet been established. In randomized phase II clinical trials to develop second-line oncology treatments, the experimental and control arms (arms E and C) should be "best supportive case (BSC) + new agent" and "BSC + placebo", and a time-to-event outcome such as PFS time is often used as the primary endpoint [16] . In some cases, a biomarker may not only be a predictive factor for a new agent but also a prognostic factor for patients with a specific cancer type. In this study, we assume that the biomarker predicts the efficacy of the new agent, but does not predict patient prognosis. That is, we consider the situation where the efficacy in the control (placebo) arm is not modified by the biomarker. However, it is not difficult to extend our proposed study design to cases where prognosis differs between subgroups.
Under these settings, we consider designing a randomized phase II trial to assess whether the addition of a new monoclonal antibody therapy to BSC sufficiently benefits the patients in terms of prolongation of PFS time. The biomarker grade is used as a stratification factor when randomization is carried out. In order to summarize the PFS data, we basically use a hazard ratio comparing arm E to arm C, which is denoted by λ.
In this study, we consider evaluating the hazard ratios in G biomarker subgroups, which are denoted by λ g , g = 1, . . . , G. Our specific goal is to find the upper subset consisting of subgroups g ≥ κ 0 , which meets the definition of the sensitive subpopulation, by evaluating these hazard ratios. Then, a subsequent phase III trial is to be conducted in the identified subpopulation. The value of cutoff κ 0 ∈ {1, . . . , G + 1} is unknown and will be determined based on data observed in the trial. As one of the two extreme cases, κ 0 = 1 suggests that arm E should be beneficial for the entire population of patients, and one can make a decision to proceed to a subsequent phase III trial that enrolls the entire population of patients. On the other hand, the cutoff κ 0 = G + 1 indicates that arm E will not be beneficial for any subgroup and the "no-go" decision to a subsequent phase III trial should be taken.
BIOMARKER-BASED BAYESIAN RANDOMIZED PHASE II STUDY DESIGN
We use the two Bayesian methods that are both based on a common probability model for PFS time. One method is based on a subgroup analysis (S-A method), and the other on a regression model (R-M method). Although Φ = (ϕ 1 , . . . , ϕ G ) is actually unknown, in the simulation study we will handle the proportions Φ as fixed values and vary the values to examine the sensitivity of simulation results to the subgroup prevalence. That is, although the proportions Φ could be handled as additional parameters to be estimated in a Bayesian study design, we will not consider them in this study.
Notation, probability model for PFS time, and Bayesian posterior computation
The two Bayesian methods explained in the next subsection commonly use the following proportional hazards model. Under the proportional hazards assumption in each subgroup, the hazard at time t for patient i with x i can be modeled as
where h 0 (t) denotes the baseline hazard function and β g denotes the regression coefficient for x i in subgroup g. According to Sinha et al. [17] and Ibrahim et al. [18] , we use the partial likelihood of the Cox proportional hazards model as the likelihood to compute the posterior distributions of the parameters in the two Bayesian methods. We used Markov chain Monte Carlo (MCMC) to compute the posteriors [19] , because the joint posterior distribution of regression coefficient parameters is not readily available in closed form.
As the criteria to identify the sensitive subpopulation, we basically use the following Bayesian posterior probability given the observed data D from the trial,
where η * is the upper limit and π * is the upper probability cutoff. These design parameters, η * and π * , need to be calibrated on the basis of operating characteristics of the study design, which are examined in simulation studies. More specifically, let D g denote the data observed in subgroup g and D all denote the data observed in all G subgroups.
Two Bayesian methods to analyze PFS time
The objective of the phase II trial is to prove the concept of a targeted therapy, that is, to evaluate whether higher efficacy of the new antibody is observed in patients with higher biomarker expression. Therefore we assume the monotonicity in the efficacy of the new antibody in both methods but in different ways.
The S-A method separately evaluates the hazard ratio in each subgroup using the data observed in that subgroup. Assuming the monotonic increase in p( 
We assume a non-informative normal prior N(0,1000) for each of the regression coefficient parameters, β 1 , . . . , β G , to perform these posterior computations.
The R-M method assumes a monotonic decrease in hazard ratio for the biomarker subgroups with the parameter constraint β 1 > β 2 > . . . > β G . In addition, this method uses the data observed in all G subgroups, D all , to evaluate the posterior distribution of
where
Assuming a non-informative normal prior N(0,1000)
for β 1 and a non-informative gamma prior Ga(0.001,0.001) with mean 1 and variance 1000 for γ 1 , . . . , γ G−1 , we compute the marginal posterior distribution of the hazard ratios. Based on the computations, we find the cutoff κ 0 to satisfy the following equation,
That is, the cutoff κ 0 is specified as the minimum of the integers g ∈ {1, . . . , G} that
Although we suppose the S-A method to have more flexibility, it may perform more poorly at identifying a sensitive subpopulation due to its subgroup-analysis approach.
In contrast, although we expect the R-M method to show a higher performance owing to the parameter constraint and the use of D all , this method may be vulnerable to departures from the monotonicity assumption. We will evaluate the advantages and disadvantages of the two methods in the simulation study.
Interim study monitoring rules
It may be important to terminate a clinical trial early from ethical and practical points of view. In the randomized phase II trial, we consider early termination of the entire trial due to futility by planning interim analyses. Although it may also be useful to consider partly terminating insensitive patient subgroups or reducing the size of those subgroups, we did not take these measures in this study. This is because it may be generally desirable to obtain sufficient data on patients in the non-selected subpopulation in order to more precisely evaluate their response to and the safety of the new treatment [20] .
The number and timing of interim analyses should be determined by taking into account the practicalities of patient enrollment rates and collecting and processing of study data. In the randomized phase II trial, we consider two interim analyses with the first and second analyses occurring after 60% and 80% of patients are recruited, respectively. When using the S-A method, given the lower probability cutoff π * stop , we consider the experimental arm to have disappointingly insufficient efficacy if
stop for all g when using the R-M method. The lower cutoff π * stop needs to be calibrated on the basis of the study design operating characteristics in the same way as the upper cutoff π * . As another interim monitoring rule, it may be useful to include early stopping for efficacy by using an efficacy stopping criterion, such as p(λ g < η * | D) > π * stop,Ef f . Due to the same reasons mentioned above, however, we will not apply this rule to the phase II trial.
EVALUATION OF OPERATING CHARACTERISTICS

Parameter calibration and simulation plan
To evaluate and compare the two Bayesian methods in the case study with four subgroups, we simulated the trial 5,000 times using extensively varying situations. We used MCMC methods to obtain samples from the posterior distributions of the parameters.
In order to complete the study design, we needed to calibrate the design parameters Table 1 , to evaluate the sensitivity of simulation results to the subgroup prevalence.
We predicted that patterns 1 and 3 were more likely to be observed in the phase II trial according to the historical data.
We assumed the five clinical scenarios for the simulation study based on hazard ratios as shown in Table 1 . Each scenario is characterized by the true (fixed) hazard ratios (HR 1 , HR 2 , HR 3 , HR 4 ) for the four subgroups. Scenario (1) is a null case, with all hazard ratios equal to 1.0. The sensitive subpopulation, found under each scenario, is indicated in boldface. In order to define the sensitive subpopulation, we first specify the efficacy threshold so that subgroup g is contained in the sensitive subpopulation if HR g ≤ the threshold. One possible way to specify the efficacy threshold may be to hold discussions with physicians regarding the published results of clinical trials, because such a specification needs to take into account the current medical environment, such as state of the art therapy and medical costs. For example, in advanced HCC, Llovet et al. [21] explored the ability of several biomarkers to predict the efficacy of a new small molecule, sorafenib, using the data from the phase III sorafenib HCC assessment randomized protocol (SHARP) trial [22] . Based on this report as well as other previous data, we solicited the opinions of the two hepatologists in the study group regarding the efficacy threshold. They suggested that the efficacy threshold = 0.6 should be clinically acceptable. We will use a power value to designate the probability of correctly identifying the target subgroup(s) as the sensitive subpopulation under alternative scenarios, and a type I error to designate the probability of identifying any subgroup(s) under the null scenario.
Taking historical data on second-line therapies for HCC into account, for the simu- 
Simulation results
In presenting the results of the simulation studies comparing the S-A and R-M methods, we summarize the probabilities of identifying i) none of the four subgroups, ii) subgroup the sensitive subpopulation; these categories are denoted by P none , P 4 , P 3−4 , P 2−4 , and P all , respectively. We chose the combination of η * = .80, π * = .70, and π * stop = 0.2, which were judged to provide the best operating characteristics for the two methods, based on the extensive simulations (as shown in Supplementary Tables in the supplementary on-line materials). Table 2 Under scenario (2) (linear), neither of the two methods worked sufficiently well, that is, P 3−4 were at most 0.50 for both methods. In cases where an obvious sensitive subpopulation may not seem to exist, such as in this scenario that assumes that the hazard ratios change steadily over subgroups, it may be hard to definitively identify the target subpopulation using either of the methods. Under scenario (3) (step-down), although both the S-A and R-M methods performed well overall, the performance of the R-M method may depend significantly on subpopulation proportions. In pattern 4 in particular, where the number of patients enrolled in subgroup 1 (non-sensitive subpopulation) was very slight, the R-M method was more likely to select all the subgroups resulting in poorer performance. Under scenario (4) (very high efficacy in subgroups 3 and 4), the R-M method selected subgroups 3 and 4 at sufficiently high probabilities across all patterns of subpopulation proportions and these probabilities were higher than or almost equal to those obtained by the S-A method. Under scenario (5) (very high efficacy only in subgroup 4), the two methods were almost comparable in terms of the probability of identifying subgroup 4 under pattern 1. In cases where the subpopulation proportion of subgroup 4 (sensitive subpopulation) was relatively high, such as in patterns 2 and 4, the R-M method performed much better than the S-A method, as expected. However, under patterns 3 and 5, in which the subpopulation proportion of subgroup 4 was small, the performance of the R-M method was lower than that of the S-A method. represents an acceptable toxicity level, may be useful. In addition, the efficacy and futility rules for stopping subgroups that we mentioned in Section 3.3 may help reduce the expected sample size of the phase II trial. This should be evaluated in future works.
Our study design was based completely on a monotonic change in treatment efficacy for biomarker subgroups. However, such a monotonicity assumption does not necessarily work in all cases. If data observed in the phase II trial indicates a non-monotonic change, such as "V-shape", the S-A method modified to select the subgroup with the highest value of p(λ g < η * | D g ) may work better than the R-M method. Otherwise, we may need to develop an alternative method based on an isotonic regression model with the pool-adjacent-violator algorithm (PAVA) [23] .
In this paper, we focused on identifying a sensitive subpopulation of patients in a randomized phase II trial to develop a new molecular-targeted anticancer agent. It may be useful to incorporate our proposed approach into a seamless phase II/III study design in order to maximize the probability of its successful development, an issue that will be examined in future works. 
